Literature DB >> 16984319

Case-only analysis of treatment-covariate interactions in clinical trials.

E Vittinghoff1, D C Bauer.   

Abstract

Differential effectiveness of treatments across subgroups defined by pretreatment variables are of increasing interest, particularly in the expanding research field of pharmacogenomics. When the pretreatment variable is difficult to obtain or expensive to measure, but can be assessed at the end of the study using stored samples, nested case-control and case-cohort methods can be used to reduce costs in large efficacy trials with rare outcomes. Case-only methods are even more efficient, and reliable under a range of circumstances.

Mesh:

Substances:

Year:  2006        PMID: 16984319     DOI: 10.1111/j.1541-0420.2006.00511.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  12 in total

1.  Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host genetics.

Authors:  James Y Dai; Shuying S Li; Peter B Gilbert
Journal:  Biostatistics       Date:  2013-06-27       Impact factor: 5.899

2.  A targeted maximum likelihood estimator for two-stage designs.

Authors:  Sherri Rose; Mark J van der Laan
Journal:  Int J Biostat       Date:  2011-03-11       Impact factor: 0.968

3.  In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities.

Authors:  Holly Janes; Peter Gilbert; Susan Buchbinder; James Kublin; Magdalena E Sobieszczyk; Scott M Hammer
Journal:  AIDS Res Hum Retroviruses       Date:  2013-06-25       Impact factor: 2.205

Review 4.  Gene--environment-wide association studies: emerging approaches.

Authors:  Duncan Thomas
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

5.  Variation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer.

Authors:  Ross L Prentice; Ying Huang; David A Hinds; Ulrike Peters; David R Cox; Erica Beilharz; Rowan T Chlebowski; Jacques E Rossouw; Bette Caan; Dennis G Ballinger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

6.  Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer.

Authors:  Ross L Prentice; Ying Huang; David A Hinds; Ulrike Peters; Mary Pettinger; David R Cox; Erica Beilharz; Rowan T Chlebowski; Jacques E Rossouw; Bette Caan; Dennis G Ballinger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-27       Impact factor: 4.254

7.  FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

Authors:  Shuying S Li; Peter B Gilbert; Georgia D Tomaras; Gustavo Kijak; Guido Ferrari; Rasmi Thomas; Chul-Woo Pyo; Susan Zolla-Pazner; David Montefiori; Hua-Xin Liao; Gary Nabel; Abraham Pinter; David T Evans; Raphael Gottardo; James Y Dai; Holly Janes; Daryl Morris; Youyi Fong; Paul T Edlefsen; Fusheng Li; Nicole Frahm; Michael D Alpert; Heather Prentice; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Merlin L Robb; Robert J O'Connell; Barton F Haynes; Nelson L Michael; Jerome H Kim; M Juliana McElrath; Daniel E Geraghty
Journal:  J Clin Invest       Date:  2014-08-08       Impact factor: 14.808

8.  Case-only trees and random forests for exploring genotype-specific treatment effects in randomized clinical trials with dichotomous endpoints.

Authors:  James Y Dai; Michael LeBlanc
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2019-07-08       Impact factor: 1.864

9.  Augmented case-only designs for randomized clinical trials with failure time endpoints.

Authors:  James Y Dai; Xinyi Cindy Zhang; Ching-Yun Wang; Charles Kooperberg
Journal:  Biometrics       Date:  2015-09-08       Impact factor: 2.571

10.  Case-only approach to identifying markers predicting treatment effects on the relative risk scale.

Authors:  James Y Dai; C Jason Liang; Michael LeBlanc; Ross L Prentice; Holly Janes
Journal:  Biometrics       Date:  2017-09-28       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.